Online citations, reference lists, and bibliographies.

The New Oral Anticoagulants In Clinical Practice.

W. Gonsalves, R. Pruthi, M. Patnaik
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for decades. However, with the US Food and Drug Administration approval of new oral anticoagulants, such as dabigatran, rivaroxaban, and apixaban, clinicians now have a broader choice. Given the recent approval and availability of these medications, several questions arise while deciding which of them would be best suited for a particular patient. This article provides a concise review for clinicians entailing the main studies that evaluated the efficacy and safety of these drugs, their pharmacokinetic and pharmacodynamic properties, and a practical approach to their clinical use. For this review, we conducted searches of PubMed and MEDLINE for articles published between January 1, 2000, and January 30, 2013, using the following search terms: oral anticoagulants, dabigatran, apixaban, rivaroxaban, novel anticoagulants, bleeding complications, management of bleeding complications, pharmacodynamics, and pharmacokinetics. Studies published in English were selected for inclusion in this review, as were additional articles identified from bibliographies.
This paper references
10.1056/NEJMoa1006885
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
M. Lassen (2010)
10.1160/TH11-01-0042
Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran.
M. C. Matute (2011)
10.1056/NEJMoa1007903
Oral rivaroxaban for symptomatic venous thromboembolism.
R. Bauersachs (2010)
10.1503/cmaj.061523
Frequency of adverse events in patients with poor anticoagulation: a meta-analysis
Natalie Oake (2007)
10.1002/ajh.23202
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors
S. Kaatz (2012)
10.1053/j.ajkd.2012.08.047
Removal of dabigatran by hemodialysis.
Don N. Chang (2013)
10.1097/MBC.0b013e32834f1b0c
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
J. Stangier (2012)
10.1016/S0140-6736(08)60880-6
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
A. K. Kakkar (2008)
10.1056/NEJMoa0800374
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
B. Eriksson (2008)
10.1161/CIRCULATIONAHA.109.853119
Update on Antithrombotic Therapy: New Anticoagulants
J. Eikelboom (2010)
10.1016/S0140-6736(07)61445-7
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
B. Eriksson (2007)
10.1056/NEJMoa1113572
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
H. Büller (2012)
10.1182/blood-2011-11-391284
HIT: treatment easier, prevention harder.
T. Warkentin (2012)
10.1007/s40262-012-0030-9
New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists
F. Scaglione (2013)
10.1093/EURHEARTJ/SUI031
Reviewing the reality: why we need to change
P. Lin (2005)
10.1160/TH10-10-0679
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
B. Eriksson (2011)
10.1056/NEJMoa1007432
Apixaban in patients with atrial fibrillation.
S. Connolly (2011)
10.1160/TH10-05-0328
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Y. C. Barrett (2010)
10.1056/NEJMoa1207541
Apixaban for extended treatment of venous thromboembolism.
G. Agnelli (2013)
10.1159/000319886
Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran
A. De Smedt (2010)
10.1016/S0140-6736(09)60734-0
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
A. Turpie (2009)
10.1111/J.1365-2125.2007.02899.X
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
J. Stangier (2007)
10.1515/cclm-2011-0888
Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests
W. Halbmayer (2012)
10.1160/TH12-03-0209
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
A. Turpie (2012)
10.1056/NEJMoa1107039
Apixaban versus warfarin in patients with atrial fibrillation.
C. Granger (2011)
10.1016/S0140-6736(10)61194-4
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
L. Wallentin (2010)
10.1161/CIRCULATIONAHA.110.977546
Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion
Rangadham Nagarakanti (2011)
10.1056/NEJMoa0905561
Dabigatran versus warfarin in patients with atrial fibrillation.
S. Connolly (2009)
10.1160/TH11-10-0718
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
M. Huisman (2012)
10.1136/EJHPHARM-2012-000074.398
Evaluation of the antifactor XA chromogenic assay for measuring rivaroxaban plasma concentrations using calibrators and controls
M. M. Samama (2012)
10.1161/CIRCULATIONAHA.111.029017
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
E. Eerenberg (2011)
10.1160/TH11-06-0391
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
M. Samama (2012)
10.1182/ASHEDUCATION.V2012.1.460.3798662
Coagulation assays and anticoagulant monitoring
Dorothy M A Funk (2012)
10.1016/j.jacc.2010.09.013
2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the Europe
V. Fuster (2011)
10.1056/NEJMoa076016
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
M. Lassen (2008)
10.1111/j.1365-2125.2012.04218.x
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.
S. Haertter (2012)
10.1016/j.arth.2008.01.132
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
Jeffrey S. Ginsberg (2009)
10.1111/j.1472-8206.2011.00981.x
Pharmacodynamic and pharmacokinetic basics of rivaroxaban
R. Kreutz (2012)
10.1182/ASHEDUCATION.V2012.1.536.3798545
New oral anticoagulants: which one should my patient use?
J. I. Weitz (2012)
10.1378/chest.11-2301
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
C. Kearon (2012)
10.1093/eurheartj/ehr342
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
K. Fox (2011)
10.1111/j.1538-7836.2010.04098.x
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
A. Hillarp (2011)
10.1160/TH11-01-0052
Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis.
F. Dentali (2011)
10.1056/NEJMoa0810773
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
M. Lassen (2009)
10.1161/CIRCULATIONAHA.111.055970
Myocardial Ischemic Events in Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin in the RE-LY Trial
S. Hohnloser (2012)
10.1111/j.1538-7836.2007.02748.x
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial
B. Eriksson (2007)
10.1111/j.1538-7836.2011.04498.x
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial
K-H Liesenfeld (2011)
10.1182/blood-2011-10-378950
How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.
S. Schulman (2012)
10.1056/NEJMoa1009638
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
M. Patel (2011)
10.1161/CIRCULATIONAHA.111.055970
Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial
S. Hohnloser (2012)
10.1160/TH10-08-0511
Rivaroxaban and false positive lupus anticoagulant testing.
E. Merriman (2011)
10.1182/BLOOD.V114.22.1065.1065
Adsorption of Dabigatran Etexilate in Water or Dabigatran in Pooled Human Plasma by Activated Charcoal in Vitro.
J. Ryn (2009)
10.1056/NEJMp1302834
Dabigatran and postmarketing reports of bleeding.
M. R. Southworth (2013)
10.1001/archinternmed.2011.1666
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.
K. Uchino (2012)
10.1160/TH10-06-0342
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
T. Lindahl (2011)
10.1016/S0140-6736(09)62125-5
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
M. Lassen (2010)
10.1160/TH09-11-0758
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
J. van Ryn (2010)
10.1182/blood-2011-05-353391
Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.
K. Krauel (2012)



This paper is referenced by
Endothermal heat-induced thrombosis (EHIT): reports on two case treated with rivaroxaban and literature review Trombose induzida pelo calor endovenoso: relato de dois casos tratados com rivaroxabana e revisão da literatura
Walter Luiz Aldá Júnior (2016)
10.1016/j.jaad.2014.11.013
Novel oral anticoagulants: what dermatologists need to know.
Molly Plovanich (2015)
10.1016/j.mayocp.2013.06.014
In reply-dabigatran for heparin-induced thrombocytopenia.
Wilson I Gonsalves (2013)
10.1160/TH15-03-0266
Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
Markus Honickel (2016)
Update on Medication Use in Older Adults
Kimberly Keefer (2016)
Investigation into Patients treated in an Oral and Maxillofacial Unit between 2012 and 2014 , who were taking the Novel Anticoagulants
Nazia Din (2019)
10.1016/J.REDAR.2015.01.002
Manejo perioperatorio de los anticoagulantes orales directos en cirugía urgente y sangrado. Monitorización y tratamiento hemostático
F. Hidalgo (2015)
10.1007/S13341-014-0410-X
Prise en charge par les services d’urgences des accidents hémorragiques graves chez les patients traités par les nouveaux anticoagulants oraux (NACOs)
A. Momo-Boma (2014)
10.1016/j.acvd.2016.08.001
Non-vitamin K antagonist oral anticoagulants and heart failure.
Richard Isnard (2016)
10.1160/TH16-11-0824
Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
Markus Honickel (2017)
10.1517/14656566.2014.884560
Small molecule inhibitors in the treatment of cerebral ischemia
J. Flores (2014)
10.1007/978-3-319-22602-6_4
Direct Oral Anticoagulants
Erin Robinson (2015)
10.1177/0885066615627141
Quick Response Tracheotomy
Graeme Browne (2016)
10.1016/j.otc.2016.02.005
Quality Control Approach to Anticoagulants and Transfusion.
Erin L Mckean (2016)
10.1007/s11910-017-0774-6
Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal
Sujan T Reddy (2017)
10.1016/j.cgh.2017.04.031
Risk of Gastrointestinal Bleeding in Patients Taking Non–Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta‐analysis
Corey S. Miller (2017)
10.1016/J.MICROC.2017.02.010
Monitoring of warfarin therapy: Preliminary results from a longitudinal pilot study
T. Lomonaco (2018)
10.1038/s41598-018-31854-z
Replacement of the L-iduronic acid unit of the anticoagulant pentasaccharide idraparinux by a 6-deoxy-L-talopyranose – Synthesis and conformational analysis
Fruzsina Demeter (2018)
10.1007/978-1-4939-3252-8_3
Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS).
Jaime H. Noguez (2016)
Lessons from the trials Hokusai-VTE : Edoxaban for the treatment of venous thromboembolism
K. Said (2014)
10.5937/SIKS1502039D
How to apply knowledge that we have: Rivaroxaban effective protection and therapy
Željko Delić (2015)
10.2174/1573403X12666160720092024
Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
Kenechukwu Mezue (2017)
10.1097/MJT.0000000000000216
Aminocaproic Acid and Tranexamic Acid Fail to Reverse Dabigatran-Induced Coagulopathy
M. Levine (2016)
10.1007/s11096-018-0734-5
Factors influencing the recruitment of lactating women in a clinical trial involving direct oral anticoagulants: a qualitative study
Yating Zhao (2018)
10.1002/JLB.MR1118-460R
Viral receptors for flaviviruses: Not only gatekeepers
L. G. Oliveira (2019)
10.1371/journal.pone.0156943
Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation – Data from the Ljubljana Registry
N. Vene (2016)
Nanoparticle systems that exploit host biology for diagnosis and treatment of disease
K. Lin (2014)
What The Vascular Specialist Need To Know About The Newer Oral Anticoagulants, Their Pitfalls And How To Use Them
D. Poldermans (2013)
10.1155/2016/1781684
Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians
W. Peacock (2016)
10.1016/j.ajem.2014.08.075
The use of oral anticoagulants for the treatment of venous thromboembolic events in an ED.
Charles V. Pollack (2014)
10.1016/j.blre.2017.02.002
Advances in oral anticoagulation therapy - What's in the pipeline?
P S S Rao (2017)
UvA-DARE ( Digital Academic Repository ) Factor XI as target for antithrombotic therapy
Boross (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar